Impact BioMedical Inc. (IBO)
NYSE American · Healthcare · Biotechnology
$4.84−9.02%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $41.4M
- P/E (trailing)
- 0.4
- 52-week range
- $4.68 – $10.51
- 52-week change
- −34.02%
- EPS (trailing)
- $11.11
Fiscal year to Dec 2025
- Revenue
- $32K
- Net income
- −$11.8M
- Operating margin
- −13381.2%
- Diluted EPS
- −$0.38
From the company’s annual report on SEC EDGAR.
About Impact BioMedical Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc.
Headquarters: Houston, United States · 2 employees · impactbiomedinc.com